Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $10.08, for a total transaction of $100,800.00. Following the completion of the transaction, the insider now owns 723,510 shares of the company’s stock, valued at $7,292,980.80. The sale was disclosed in a filing with the SEC, which is available at this link.
Sharon Shacham also recently made the following trade(s):
- On Thursday, December 7th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $10.39, for a total transaction of $103,900.00.
Shares of Karyopharm Therapeutics Inc (NASDAQ KPTI) opened at $11.82 on Thursday. Karyopharm Therapeutics Inc has a 52-week low of $7.48 and a 52-week high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. equities research analysts predict that Karyopharm Therapeutics Inc will post -2.58 EPS for the current year.
Several equities analysts have recently weighed in on KPTI shares. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 12th. assumed coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They set a “buy” rating and a $23.00 target price on the stock. BidaskClub lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $17.33.
Several hedge funds have recently added to or reduced their stakes in KPTI. Vanguard Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 31.1% in the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after acquiring an additional 384,658 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Karyopharm Therapeutics by 753.5% in the third quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after purchasing an additional 271,208 shares in the last quarter. Tekla Capital Management LLC raised its holdings in Karyopharm Therapeutics by 25.0% in the second quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock worth $6,848,000 after purchasing an additional 151,455 shares in the last quarter. Northern Trust Corp raised its holdings in Karyopharm Therapeutics by 36.5% in the second quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock worth $3,668,000 after purchasing an additional 108,369 shares in the last quarter. Finally, Iguana Healthcare Management LLC raised its holdings in Karyopharm Therapeutics by 33.3% in the third quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 60.92% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Insider Selling: Karyopharm Therapeutics Inc (NASDAQ:KPTI) Insider Sells 10,000 Shares of Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/01/karyopharm-therapeutics-inc-kpti-insider-sells-100800-00-in-stock.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.